![](https://factor-h.org/wp-content/uploads/2024/07/Screenshot-2024-07-10-at-14.20.40-300x168.png)
Factor-H
Uniqure’s AMT-130 Phase 1/2 trial – a reflection
Yesterday, Uniqure reported on the 24-month results of their Phase 1/2 clinical trial with AMT-130, a viral gene therapy trial
Yesterday, Uniqure reported on the 24-month results of their Phase 1/2 clinical trial with AMT-130, a viral gene therapy trial
Dilia Oviedo Güillín, a woman of unwavering spirit and strength, always dreamed of reuniting her deceased husband and children in
Team work and scientific education Every year, Factor-H Vice President Roger Cachope and I visit the Colombian & Venezuelan communities
Factor-H is a registered 501-(c)3 non-profit foundation in the United States (EIN 82-5395108)